Mehul Dalal
YOU?
Author Swipe
View article: Mental Effects Aside, We Got to Handle Physical Dangers Too When it Comes to Digital Devices Like a Phone
Mental Effects Aside, We Got to Handle Physical Dangers Too When it Comes to Digital Devices Like a Phone Open
In today’s digital age, mobile phones have become an integral part of daily life, often used during rest or while lying in bed. However, what seems like a harmless habit can lead to significant injuries, especially involving the eyes. When…
View article: Real-World Treatment Patterns, Clinical Outcomes, and Costs in Patients with Higher-Risk Myelodysplastic Syndromes Across France, Germany, and the United Kingdom
Real-World Treatment Patterns, Clinical Outcomes, and Costs in Patients with Higher-Risk Myelodysplastic Syndromes Across France, Germany, and the United Kingdom Open
These results provide real-world data from France, Germany, and the UK on HR-MDS treatment patterns, clinical outcomes, and costs.
View article: Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison Open
Background Ponatinib and asciminib are approved for third-line therapy in chronic-phase chronic myeloid leukemia (CP-CML) and are the only drugs approved for patients with the T315I mutation in the United States. In Europe, only ponatinib …
View article: Neovascular glaucoma in diabetic retinopathy
Neovascular glaucoma in diabetic retinopathy Open
Neovascular glaucoma (NVG) is sight threatening form of secondary glaucoma, characterised by development of new vessels over the iris and anterior chamber angle that can obstruct aqueous humour outflow and increase the intraocular pressure…
View article: Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research
Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research Open
Not available.
View article: A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom
A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom Open
(1) Background: Most patients with mycosis fungoides (MF), a form of cutaneous T-cell lymphoma (CTCL), develop relapsed/refractory (R/R) disease following front-line systemic therapy. This report describes treatment patterns and outcomes f…
View article: A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom
A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom Open
(1) Background: Most patients with mycosis fungoides (MF), a form of cutaneous T-cell lym-phoma (CTCL), develop relapsed/refractory (R/R) disease following front-line systemic therapy. This report describes treatment patterns and outcomes …
View article: Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes Open
Not available.
View article: Clinical Impact of Transformation to Acute Myeloid Leukemia in Patients With Higher-Risk Myelodysplastic Syndromes
Clinical Impact of Transformation to Acute Myeloid Leukemia in Patients With Higher-Risk Myelodysplastic Syndromes Open
Aim: Forty percent of patients with higher-risk myelodysplastic syndromes (HR-MDS) transform to acute myeloid leukemia (AML). Materials & methods: This retrospective study assessed the impact of HR-MDS transformation to AML on OS in a 6-mo…
View article: Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC study
Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC study Open
Information on Hodgkin lymphoma (HL) is mostly limited to Europe and North America. This real-world, retrospective study assessed treatment pathways and clinical outcomes in adults with stage IIB-IV classical HL receiving frontline treatme…
View article: First‐line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes
First‐line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes Open
Classical Hodgkin lymphoma (cHL) is curable in 90% of cases, but advanced stage patients who do not respond well to first‐line (1L) therapy have poorer outcomes. This retrospective study examines patient characteristics, treatment patterns…
View article: Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States
Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States Open
Daniel Auclair,1,* Carol Mansfield,2,* Mark A Fiala,3,* Ajai Chari,4 Craig E Cole,5 Jonathan L Kaufman,6 Gregory J Orloff,7 David S Siegel,8 Jeffrey A Zonder,9 Brennan Mange,2 Jennifer Yesil,1 Mehul Dalal,10 Joseph R Mikhael11 1Department …
View article: Patient preferences for frontline therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia: a discrete choice experiment
Patient preferences for frontline therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia: a discrete choice experiment Open
Aim: We examined the preferences of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for benefits and risks of tyrosine kinase inhibitors combined with chemotherapy for first-line treatment. Methods: In a…
View article: Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries
Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries Open
The treatment pattern of cutaneous T-cell lymphoma (CTCL) remains diverse and patient-tailored. The objective of this study was to describe the treatment patterns and outcomes in CTCL patients who were refractory or had relapsed (R/R) afte…
View article: The Clinical and Economic Burden of Peripheral T-Cell Lymphoma: a Systematic Literature Review
The Clinical and Economic Burden of Peripheral T-Cell Lymphoma: a Systematic Literature Review Open
Aim: To understand the burden of treatment-naive peripheral T-cell lymphoma (PTCL). Methods: A systematic literature review was conducted in November 2020 following best practice methodology. Results: Fifty-five clinical studies were inclu…
View article: Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review
Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review Open
New therapies, such as A+AVD, maintain the efficacy observed with current treatments, and may provide a more tolerable treatment option for patients with advanced-stage HL.
View article: Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment
Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment Open
A cross-sectional online survey, including a discrete choice experiment (DCE), was used to investigate first-line treatment preferences in patients with classical Hodgkin lymphoma (cHL) in the United States; 141 patients (median age 35.0 y…
View article: Developing a COVID-19 Medical Respite Unit for Adults Experiencing Homelessness: Lessons Learned from an Interdisciplinary Community-Academic Partnership
Developing a COVID-19 Medical Respite Unit for Adults Experiencing Homelessness: Lessons Learned from an Interdisciplinary Community-Academic Partnership Open
Individuals experiencing homelessness are at particularly high risk for infection, severe illness, and death from COVID19. Local public health initiatives to address the pandemic should include medical respite services for individuals expe…
View article: The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review
The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review Open
Objectives: To summarize the impact of relapsed/refractory primary cutaneous T-cell lymphomas (CTCL) on quality of life (QoL) and the efficacy of available treatments in two systematic reviews (SRs).Methods: Searches were performed on 16 J…
View article: The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review
The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review Open
Objectives: To summarize the impact of relapsed/refractory primary cutaneous T-cell lymphomas (CTCL) on quality of life (QoL) and the efficacy of available treatments in two systematic reviews (SRs). Methods: Searches were performed on 16 …
View article: Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom
Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom Open
INTRODUCTION Peripheral T cell lymphomas (PTCL) are a rare and heterogenous group of aggressive non-Hodgkin lymphomas (NHL) that develop from mature T- and natural killer cells. They comprise approximately 10% of all newly diagnosed cases …
View article: PS1256 CONTEMPORARY TREATMENT PATTERNS AND RESPONSE IN RELAPSE/REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL) IN CLINICAL PRACTICE IN FRANCE, GERMANY ITALY, SPAIN AND THE UNITED KINGDOM
PS1256 CONTEMPORARY TREATMENT PATTERNS AND RESPONSE IN RELAPSE/REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL) IN CLINICAL PRACTICE IN FRANCE, GERMANY ITALY, SPAIN AND THE UNITED KINGDOM Open
Background: Effective treatment for relapsed, refractory mantle cell lymphoma (MCL) post Bruton's Tyrosine Kinase inhibitor (BTKi) therapy represents an unmet clinical need with studies consistently reporting dismal outcome. No treatment s…
View article: Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice
Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice Open
Objective. Many patients with type 2 diabetes do not reach glycemic goals despite basal insulin treatment. This study assessed the achievement of a target A1C <7.0% (<53 mmol/mol) after initiation of basal insulin in two settings. Me…
View article: Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom
Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom Open
Summary First‐line treatments for classical Hodgkin lymphoma ( HL ) include ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPP escalated (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, proca…